306 related articles for article (PubMed ID: 23794019)
1. Aggregation formation in the polyglutamine diseases: protection at a cost?
Todd TW; Lim J
Mol Cells; 2013 Sep; 36(3):185-94. PubMed ID: 23794019
[TBL] [Abstract][Full Text] [Related]
2. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.
Kvam E; Nannenga BL; Wang MS; Jia Z; Sierks MR; Messer A
PLoS One; 2009 May; 4(5):e5727. PubMed ID: 19492089
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going?
Takahashi T; Katada S; Onodera O
J Mol Cell Biol; 2010 Aug; 2(4):180-91. PubMed ID: 20410236
[TBL] [Abstract][Full Text] [Related]
4. Conformational diseases: structural studies of aggregation of polyglutamine proteins.
Papaleo E; Invernizzi G
Curr Comput Aided Drug Des; 2011 Mar; 7(1):23-43. PubMed ID: 20807186
[TBL] [Abstract][Full Text] [Related]
5. Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders.
Weydt P; La Spada AR
Expert Opin Ther Targets; 2006 Aug; 10(4):505-13. PubMed ID: 16848688
[TBL] [Abstract][Full Text] [Related]
6. Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases.
Li X; Li H; Li XJ
Brain Res Rev; 2008 Nov; 59(1):245-52. PubMed ID: 18773920
[TBL] [Abstract][Full Text] [Related]
7. Misfolded polyglutamine, polyalanine, and superoxide dismutase 1 aggregate via distinct pathways in the cell.
Polling S; Mok YF; Ramdzan YM; Turner BJ; Yerbury JJ; Hill AF; Hatters DM
J Biol Chem; 2014 Mar; 289(10):6669-6680. PubMed ID: 24425868
[TBL] [Abstract][Full Text] [Related]
8. Progressive disruption of cellular protein folding in models of polyglutamine diseases.
Gidalevitz T; Ben-Zvi A; Ho KH; Brignull HR; Morimoto RI
Science; 2006 Mar; 311(5766):1471-4. PubMed ID: 16469881
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation.
Herbst M; Wanker EE
Curr Pharm Des; 2006; 12(20):2543-55. PubMed ID: 16842177
[TBL] [Abstract][Full Text] [Related]
10. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor.
Pollitt SK; Pallos J; Shao J; Desai UA; Ma AA; Thompson LM; Marsh JL; Diamond MI
Neuron; 2003 Nov; 40(4):685-94. PubMed ID: 14622574
[TBL] [Abstract][Full Text] [Related]
11. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
Nagai Y; Popiel HA
Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
[TBL] [Abstract][Full Text] [Related]
12. Toward an understanding of polyglutamine neurodegeneration.
Paulson HL
Brain Pathol; 2000 Apr; 10(2):293-9. PubMed ID: 10764049
[TBL] [Abstract][Full Text] [Related]
13. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity.
Mishra A; Dikshit P; Purkayastha S; Sharma J; Nukina N; Jana NR
J Biol Chem; 2008 Mar; 283(12):7648-56. PubMed ID: 18201976
[TBL] [Abstract][Full Text] [Related]
14. Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease.
Chow MK; Ellisdon AM; Cabrita LD; Bottomley SP
J Biol Chem; 2004 Nov; 279(46):47643-51. PubMed ID: 15345714
[TBL] [Abstract][Full Text] [Related]
15. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
[TBL] [Abstract][Full Text] [Related]
16. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
Wyttenbach A
J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
[TBL] [Abstract][Full Text] [Related]
17. The Cytotoxicity and Clearance of Mutant Huntingtin and Other Misfolded Proteins.
Folger A; Wang Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831058
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cell death in polyglutamine expansion diseases.
Lipinski MM; Yuan J
Curr Opin Pharmacol; 2004 Feb; 4(1):85-90. PubMed ID: 15018844
[TBL] [Abstract][Full Text] [Related]
19. Na+/H+ exchangers induce autophagy in neurons and inhibit polyglutamine-induced aggregate formation.
Togashi K; Wakatsuki S; Furuno A; Tokunaga S; Nagai Y; Araki T
PLoS One; 2013; 8(11):e81313. PubMed ID: 24278418
[TBL] [Abstract][Full Text] [Related]
20. Nuclear accumulation of polyglutamine disease proteins and neuropathology.
Havel LS; Li S; Li XJ
Mol Brain; 2009 Jul; 2():21. PubMed ID: 19575804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
